CTRI/2010/091/000001已完成未知
An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentric experimental bioequivalence study comparing Quetiapine film coated tablets 300 mg (Manufactured by Intas Pharmaceuticals Ltd., India) to the reference listed drug Seroquel® film coated tablets 300mg (Manufactured by AstraZeneca USA) under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 600 mg per day. - NA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Written informed consent for participation in the study by the patient and Patient?s Legally Authorized Representative (LAR).
- •2.Schizophrenic patients, between 18 and 60years of age (inclusive).
- •3.Patient has a documented clinical diagnosis of schizophrenia (DSM IV-TR) on a stable dose of Quetiapine 600 mg per day for at least 10 days prior to screening.
- •4.Having a Body Mass Index (BMI) between 18 and 30 (inclusive), calculated as weight in kg / height in m2.
- •5.Not having any significant diseases or clinically significant abnormal findings except schizophrenia during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (postero-anterior view) recordings.
- •6.The investigator must ensure that the respective hepatic, renal, haematopoietic, cardiac and respiratory functions are appropriate to include the patient in the study.
- •7.Able to comply with study procedures in the opinion of the investigator.
- •8.In case of female patient the serum pregnancy test at screening visit and urine pregnancy test at day 1 and day 5 (before dosing) must be negative.
排除标准
- •1.Known hypersensitivity or idiosyncratic reaction to Quetiapine and its excipients.
- •2.Current or relevant history of serious, severe or unstable psychiatric illness (Meeting the criteria for any other (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Axis I) except schizophrenia.
- •3.Presence of Postural Hypotension (Defined as systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing up).
- •4.History of syncope or orthostatic hypotension.
- •5.Smokers who smoke 10 or more than 10 cigarette/day or inability to abstain from smoking during the study.
- •6.The presence of clinically significant abnormal laboratory values during screening.
- •7.Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose of study medication or during the study.
- •Note: In case the blood loss is less than or equal to 200 mL; Patient may be dosed 60 days after blood donation.
- •8.A positive hepatitis screen including hepatitis B surface antigen, HCV and HAV IgM antibodies.
- •9.Known case of HIV infection.
- •10.Supine blood pressure less than 110/70 mm Hg or pulse rate less than 60 or more than 100 beats per minute at screening.
- •11.Presence of cataract on Opthalmoscopic examination (slit lamp exam).
- •12.History of seizures.
- •13.History of agranulocytosis.
- •14.Patients having Hypertension or on any antihypertensive medication.
- •15.Patients with Diabetes mellitus or fasting blood glucose ≥ 126 mg/dl at screening visit.
- •16.Patients with abnormal thyroid function test at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
- •17.Patient with hyperprolactinemia at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
- •18.Dementia related psychosis.
- •19.Pregnant or lactating females.
研究者
相似试验
已完成
2 期
An open label, balanced, randomized, two treatment, two period, two sequence, cross over, comparative bioavailability study of a single dose of commercially available 6 gm Curcumin hard gelatin capsules (each capsule contains 500 mg of Curcumin 95%) and 6 gm Curcumin soft gelatin capsules (each capsule contains 750 mg of Curcumin 95%) of Amsar Private Limited, in healthy human adult male subjects under fed condition.CTRI/2009/091/000327Amsar Private limited30
已完成
不适用
A Bioequivalence study to compare the Bioequivalence of two formulation of quetiapine in schizophrenic patients.CTRI/2010/091/000181Dr Reddys Laboratories Ltd India54
已完成
不适用
A Bioequivalence study of two formulations of Quetiapine film coated tablets in adultschizophrenic patientsCTRI/2012/05/002632Hetero Labs Limited54
招募中
不适用
Bioequivalencestudy of Lomustine 40mg capsulesCTRI/2022/11/047029Carnegie Pharmaceuticals
招募中
不适用
Bioequivalence study ofCapecitabine tablets 500 mgCTRI/2018/05/014342Mega Pharma SA